You are here

  • Home
  • Archive
  • Volume 33, Issue 8
  • Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database

Article metrics

Article menu
Download PDFPDF
Original research
Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database

 

Online download statistics by month:

Online download statistics by month: May 2023 to September 2024

AbstractFullPdf
May 20236691916
Jun 202319774
Jul 202313153
Aug 20237492512
Sep 20233281916
Oct 202317053
Nov 202345510
Dec 202324665
Jan 202411652
Feb 202412411
Mar 202414734
Apr 202413932
May 202410543
Jun 202412243
Jul 202411732
Aug 20248810
Sep 20244322
Total394611378